The Law Offices of Frank R. Cruz continues its investigation on behalf of Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE: GMED) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On August 13, 2024, the FDA published a warning letter to Globus Medical regarding an inspection of the Company’s Class II Excelsius GPS (EGPS) surgical robot, stating that the inspection revealed that “these devices are adulterated” and are not in conformity with quality system regulation requirements.
On this news, Globus Medical’s stock price fell $5.73, or 7.8%, to close at $67.32 per share on August 13, 2024, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased Globus Medical securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108999131/en/